In response to earlier studies linking decreased 5-HT neurotransmission and/or 5-HT receptor dysfunction to PE, Janssen et al. investigated polymorphisms of the 5-HT transporter-linked promoter ...

Lundbeck will buy Longboard Pharmaceuticals and its 5-HT 2C receptor agonist bexicaserin, which is currently in phase III development for seizures associated with Dravet syndrome. The deal ...

However, this work concentrated on only one serotonin receptor, the 5-HT 4 receptor. The researchers began by scanning the ...

“Non-hallucinogenic 5-HT receptor agonists have garnered a great deal of attention in recent years, and we are eager to ...

HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Inc. (NASDAQ: DRUG), a ...